Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ajinomoto Of Japan Buys Rights To P&G Osteo Drug For $210 Million

This article was originally published in PharmAsia News

Executive Summary

Japan's Ajinomoto has agreed to pay $210 million for the rights to an osteoporosis drug from U.S.-based Procter & Gamble. The drug involved is P&G's Actonel (risedronate). With the agreement, Ajinomoto gets to take the drug from the research stage through marketing. While P&G phases out of the pharmaceutical business, Ajinomoto is moving into it, an expansion beyond its basic business of making seasonings. Takeda Pharmaceutical also makes risedronate and markets it in Japan as Benet. (Click here for more

You may also be interested in...



UK Price Increases Add To Pharmacy Burden

A lengthening list of concession prices granted in the UK this year has added to the burden on pharmacists, according to the annual report of the country’s Pharmaceutical Services Negotiating Committee.

QUOTED. 13 December 2019. Todd Garner

ConMed's CFO Todd Garner told delegates at the Jefferies Healthcare conference that the company's orthopedic franchise is focused on its pipeline and meeting customer's needs.  See what the CFO said about it here.

Sarepta Scores Another Remarkable Approval With Vyondys 53 For Duchenne

Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.

UsernamePublicRestriction

Register

SC072355

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel